Prothena Corp Public (PRTA) EPS (Weighted Average and Diluted) (2013 - 2026)
Prothena Corp Public (PRTA) recorded quarterly EPS (Weighted Average and Diluted) of $0.6 in Q1 2026, up 250.0% quarter-over-quarter from -$0.4 in Q4 2025, and up 153.57% on a YoY basis from $0.24 in Q1 2025.
Prothena Corp Public (PRTA) EPS (Weighted Average and Diluted) (2013 - 2026) Analysis & Trends
Prothena Corp Public's EPS (Weighted Average and Diluted) history runs 11 years deep, the most recent figure standing at $0.6 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 153.57% year-over-year to $0.6; the TTM figure through Mar 2026 stood at -$2.82 (down 36.23% YoY), while the FY2025 annual figure was -$4.53, down 99.56% from the prior year.
- EPS (Weighted Average and Diluted) was $0.6 for Q1 2026 at Prothena Corp Public, up from -$0.4 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.22 in Q2 2024 to a low of -$2.34 in Q2 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.68 across 5 years, with a median of -$0.89 in 2023.
- The sharpest annual moves came in 2023 and 2024: EPS (Weighted Average and Diluted) plunged 887.5% in 2023, then jumped 218.45% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.16 in 2022, then slumped by 887.5% to -$1.26 in 2023, then gained by 15.08% to -$1.07 in 2024, then soared by 62.62% to -$0.4 in 2025, then jumped by 250.0% to $0.6 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.6 (Q1 2026), -$0.4 (Q4 2025), and -$0.68 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 0.60 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.60 |
| Dec 31, 2025 | -0.40 |
| Sep 30, 2025 | -0.68 |
| Jun 30, 2025 | -2.34 |
| Mar 31, 2025 | -1.12 |
| Dec 31, 2024 | -1.07 |
| Sep 30, 2024 | -1.10 |
| Jun 30, 2024 | 1.22 |
| Mar 31, 2024 | -1.34 |
| Dec 31, 2023 | -1.26 |
| Sep 30, 2023 | 0.38 |
| Jun 30, 2023 | -1.03 |
| Mar 31, 2023 | -0.89 |
| Dec 31, 2022 | 0.16 |
| Sep 30, 2022 | -0.97 |
| Jun 30, 2022 | -0.88 |
| Mar 31, 2022 | -0.78 |
| Dec 31, 2021 | -0.74 |
| Sep 30, 2021 | 2.13 |
| Jun 30, 2021 | 0.58 |